Discontinued — last reported Q1 '18
Dover Allowance for Doubtful Accounts Receivable (Current) increased by 5.7% to $37.44M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.9%, from $34.71M to $37.44M. Over 5 years (FY 2020 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows a downward trend with a -2.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $40.53M | $41.60M | $40.13M | $40.32M | $37.39M | $36.40M | $39.40M | $40.33M | $38.45M | $33.96M | $31.51M | $33.48M | $31.57M | $30.10M | $28.79M | $34.71M | $37.91M | $35.34M | $35.42M | $37.44M |
| QoQ Change | — | +2.6% | -3.5% | +0.5% | -7.3% | -2.7% | +8.3% | +2.4% | -4.7% | -11.7% | -7.2% | +6.3% | -5.7% | -4.7% | -4.3% | +20.5% | +9.2% | -6.8% | +0.2% | +5.7% |
| YoY Change | — | — | — | — | -7.8% | -12.5% | -1.8% | +0.0% | +2.8% | -6.7% | -20.0% | -17.0% | -17.9% | -11.4% | -8.6% | +3.7% | +20.1% | +17.4% | +23.0% | +7.9% |